Are Your Patients Getting Diagnosed Too Late? What Pharmacists Can Do About It

Every 3 minutes, someone in the United States receives a blood cancer diagnosis.¹ Yet 76% of patients don’t initially realize their condition is a blood cancer, and 31% visit their primary care provider 3 or more times before diagnosis.²

September marks Blood Cancer Awareness Month—an observance aimed at raising awareness of leukemia, lymphoma, and multiple myeloma, 3 cancers that together affect nearly 1.3 million Americans.³

For pharmacists working in primary care and community settings, this awareness gap presents both a challenge and an opportunity—because pharmacists are often the first clinical professional a patient encounters with vague symptoms that could signal blood cancer.

What Are the 3 Main Blood Cancers, and How Do They Differ?

Leukemia originates in white blood cells in the bone marrow; lymphoma develops in lymphocytes of the lymphatic system; and multiple myeloma arises in plasma cells.¹ While they originate in different cell types, symptoms overlap substantially—fatigue, fever, unexplained bleeding or bruising, recurrent infections, and swollen lymph nodes can appear in any of them.¹

This overlap makes differentiation difficult at the counter level, which is precisely why pharmacists should not attempt to distinguish between them but instead recognize the symptom cluster as a red flag warranting medical evaluation.

What Symptoms Should Trigger a Pharmacist Referral to a Primary Care Provider?

When a patient presents with unexplained fatigue lasting weeks, persistent fever, unusual bleeding or bruising, recurrent infections, night sweats, unintended weight loss, shortness of breath, or swollen lymph nodes—particularly in combination—these warrant escalation beyond over-the-counter counseling.²

Pharmacists dispensing products for fatigue, pain, or fever should gently explore whether the symptom pattern is new or persistent, and if so, encourage a medical visit.

Why Is Diagnostic Delay so Harmful in Blood Cancer?

The 31% of patients who visit their provider 3 or more times before diagnosis experience prolonged suffering while the disease progresses unchecked.¹

For acute leukemias, which can progress rapidly, delay means cells multiply while patients seek answers. For lymphomas and myelomas, which grow more slowly, delay may still affect staging and prognosis at the time of treatment initiation. Early detection and intervention significantly improve outcomes in many cases, making each lost month clinically meaningful.

How Can Pharmacists Streamline Care for Patients With Blood Cancer?

Pharmacists are integral to blood cancer care—managing complex medication regimens with narrow therapeutic indices, monitoring for chemotherapy-related side effects, including nausea and infection risk, ensuring adherence to oral oncolytics like ibrutinib or venetoclax, and coordinating prophylactic antimicrobials and supportive care agents.⁴ Studies show that pharmacist-led interventions reduce adverse events, improve adherence, and lower hospital readmissions.⁴

How Can Pharmacists Use September to Make a Tangible Difference?

Engage patients about their symptom patterns—not just the OTC product they’re buying; use this month to review your practice’s protocols for oral oncolytic dispensing and drug interaction management; and remind colleagues in primary care settings that unusual bleeding, persistent fever, and unexplained fatigue deserve a CBC before attributing them to stress or seasonal illness.

REFERENCES

1. National Cancer Institute. Leukemia, lymphoma, and multiple myeloma. Accessed September 1, 2026. https://www.cancer.gov/types/blood/

2. US Pharmacist. Highlighting hematological cancers. Published August 27, 2025. Accessed September 1, 2026. https://www.uspharmacist.com/article/highlighting-hematological-cancers

3. Blood Cancer United. Blood cancer facts and statistics. Updated 2026. Accessed September 1, 2026. https://bloodcancerunited.org/blood-cancer/blood-cancer-facts-and-statistics

4. US Pharmacist. Role of the pharmacist in blood cancer treatment. Published September 17, 2025. Accessed September 1, 2026. https://www.uspharmacist.com/article/role-of-the-pharmacistin-blood-cancer-treatment-2025